



www.omgene.com

LIST OF PEPTIDE API

Molecules*	Therapeutic class	Stage	Commercial For
Leuprolide Acetate USP	GnRH agonist and an antineoplastic agent	Commercial	ROW
Octreotide Acetate USP/EP	Treatment of Acromegaly and Carcinoid Tumors	Commercial	ROW
Ganirelix Acetate	GnRH antagonist	Commercial	ROW
Triptorelin Pamoate/Acetate	GnRH agonist and an antineoplastic agent	Commercial	ROW
Cetorelix Acetate	GnRH antagonist and an antineoplastic agent	Commercial	ROW
Degarelix Acetate	GnRH antagonist and an antineoplastic agent	Commercial	ROW
Goserelin BP	GnRH antagonist and an antineoplastic agent	Commercial	ROW
Desmopressin USP/EP/IP	Anti-diuretic	Commercial	ROW
Exenatide USP	Antidiabetic, GLP1 receptor agonist	Commercial	ROW
Terlipressin Acetate EP	improve kidney function during hepatorenal syndrome	Commercial	ROW
Vasopressin USP/IP	Antidiuretic hormone	Commercial	ROW
Teriparatide USP/EP/IP	Treatment of osteoporosis in postmenopausal women	Commercial	ROW
Buserelin BP /IP	used in prostate cancer treatment	Commercial	ROW
Bivalirudin	Anti-coagulant/Anti-thrombin	Commercial	ROW
Glatiramer Acetate	Used in treatment of multiple sclerosis	Commercial	ROW
Atosiban Acetate IP	Labour repressant	Commercial	ROW
Carbetocin	To treat postpartum bleeding	Commercial	ROW
Linaclotide	Constipation treatment	R&D Quantity Available, Scale-up completed	ROW
Carfilzomib	Anticancer	R&D Quantity Available, Scale-up completed	ROW
Etelcalcetide HCl	Used in secondary hyperparathyroidism treatment	R&D Quantity Available, Scale-up completed	ROW
Plecanatide	Used to treat chronic idiopathic constipation	R&D Quantity Available, Scale-up completed	ROW
Lanreotide Acetate	Treatment of Acromegaly	R&D Quantity Available, Scale-up completed	ROW
Setmelanotide	Used in treatment of obesity	R&D Quantity Available, Scale-up completed	ROW


LIST OF PEPTIDE API

Molecules*	Therapeutic class	Stage	Commercial For
Felypressin	Used as local anaesthetic for dental treatment	R&D Quantity Available, Scale-up completed	ROW
Liraglutide	Type II anti-Diabetic	R&D Quantity Available, Under Scale-up	ROW
Abaloparatide	Treatment of osteoporosis	R&D Quantity Available, Under Scale-up	ROW
Semaglutide	Used in treatment of Type II anti-Diabetic and obesity	R&D Quantity Available, Under Scale-up	ROW
Difelikefalin	To treat itching during chronic kidney disease	Development completed	—
Bremelanotide	To treat hypoactive sexual desire disorder in women	Development completed	—
Cagrilintide	Anti-obesity	Development completed	—
Pasireotide	Somatostatin agonists, treatment of Cushing's disease	Development completed	—
Trofinetide	Treat rett syndrom	Development completed	—
Dulaglutide	Antidiabetic	Under Planning	—

*Developed for US/Eu/ROW markets.

LIST OF SEMI-SYNTHETIC API

Molecules*	Therapeutic class	Stage	Commercial For
Micafungin Sodium USP	Antifungal	Commercial	ROW
Anidulafungin Fructose	Antifungal	Commercial	ROW
Everolimus	Immunosuppressant	R&D Quantity Available, Scale-up completed	—
Obeticholic acid	Treatment of Primary Biliary Cholangitis	R&D Quantity Available, Scale-up completed	—
Midostaurin	Anticancer	R&D Quantity Available, Scale-up completed	—
Sarecycline	Antibiotic	R&D Quantity Available, Scale-up completed	—
Dalbavancin	Antibacterial	R&D Quantity Available, Under Scale-up	—
Voclosporine	Treatment of Lupus nephritis	R&D Quantity Available, Under Scale-up	—



LIST OF SEMI-SYNTHETIC API			
Molecules*	Therapeutic class	Stage	Commercial For
Rezafungin Acetate	Anti Fungal	Development Completed	—
Omadacycline	Antibiotic	Development Completed	—
Ibrexafungerp Citrate	Anti Fungal	Development Completed	—

*Developed for US/Eu/ROW markets.


LIST OF OLIGONUCLEOTIDES			
Molecules*	Therapeutic class	Stage	Commercial For
Nusinersen	Treatment of spinal muscular atrophy (SMA)	Under Development	—
Patisiran	Treatment of polyneuropathy of hereditary transthyretinmediated amyloidosis in adults	Under Development	—
Inclisiran	Antilipemic agent	Under development	—

*Developed for US/Eu/ROW markets.

LIST OF RECOMBINANT PEPTIDES			
Molecules*	Therapeutic class	Stage	Commercial For
Semaglutide	Type II anti-Diabetic	Under Development	—
Liraglutide	Type II anti-Diabetic	Under Development	—

*Developed for US/Eu/ROW markets.

LIST OF SYNTHETIC API			
Molecules*	Therapeutic class	Stage	Commercial For
Mebendazole, Form A	Anthelmintic	Commercial	ROW
Bedaquiline	Antituberculosis	Commercial	ROW



LIST OF SYNTHETIC API

Molecules*	Therapeutic class	Stage	Commercial For
Sugammadex Sodium	Reversal of neuromuscular blocker	Out-licensed, R&D Quantity Available, Scale-up completed	—
Isavuconazonium sulfate	Antifungal	R&D Quantity Available, Scale-up completed	—
Saroglitazar Calcium	Antidiabetic	R&D Quantity Available, Scale-up completed	—
Nitisinone	For the treatment of hereditary tyrosinemia type 1	R&D Quantity Available, Scale-up completed	—
SNAC	Oral peptide absorption promoter	R&D Quantity Available, Scale-up completed	—
Deutetrabenazine	Management of chorea associated with Huntington's disease	R&D Quantity Available, Scale-up completed	—
Rufinamide	Anti-epileptic	R&D Quantity Available, Scale-up completed	—
Selexipag	Treatment of pulmonary arterial hypertension (PAH)	R&D Quantity Available, Scale-up completed	—
Vismodegib	For the treatment metastatic basal cell carcinoma	R&D Quantity Available, Scale-up completed	—
Baricitinib	For the treatment of rheumatoid arthritis.	R&D Quantity Available, Scale-up completed	—
Brexanolone	For the treatment of postpartum depression in women	R&D Quantity Available, Scale-up completed	—
Midodrine	Vasoconstrictor agent in the treatment of hypotension.	R&D Quantity Available, Scale-up completed	—
Crisaborole	Antipsoriatic and a non-steroidal anti-inflammatory drug	R&D Quantity Available, Scale-up completed	—
Nintedanib Mesylate	For the treatment of idiopathic pulmonary fibrosis	R&D Quantity Available, Scale-up completed	—
Erdaftinib	For the treatment of metastatic urothelial carcinoma	R&D Quantity Available, Scale-up completed	—
Vonoprazan	Potassium-competitive acid blocker (PCAB)	R&D Quantity Available, Scale-up completed	—
Venetoclax	For treatment of chronic lymphocytic leukemia with 17p deletion	R&D Quantity Available, Scale-up completed	—

LIST OF SYNTHETIC API

Molecules*	Therapeutic class	Stage	Commercial For
Delamanid	Antimycobacterial	Development Completed	—
Binimetinib	For the treatment of unresectable or metastatic melanoma	Development Completed	—

*Developed for US/Eu/ROW markets.

LIST OF FORMULATIONS UNDER DEVELOPMENT

LIQUID INJECTABLES

- Carbetocin injection, 100 micrograms/mL
- Brexanolone injection, 100 mg in 20 mL (5 mg/mL) as aqueous solution
- Sugammadex injection 200 mg/2 mL and 500 mg/5 mL (100 mg/mL) in a single-dose vial
- Ganirelix Acetate injection in prefilled glass syringe containing 250 micrograms/0.5 mL as aqueous solution
- Semaglutide Injection, 0.5 mg/mL, 0.68 mg/mL, 1.0 mg/mL, 1.34 mg/mL, 2.0 mg/mL, 2.27 mg/mL, 2.68 mg/mL and 3.2 mg/mL
- Leuprolide acetate injection, 5 mg/mL
- Triptorelin acetate injection, 100 micrograms/mL

LYOPHILIZED INJECTIONS

- Cetrorelix for injection, 0.25 mg cetrorelix/ vial
- Micafungin for injection, 50 mg & 100 mg/vial
- Anidulafungin for injection, 50 mg & 100 mg/vial
- Degarelix for injection, 80 mg & 120 mg/vial
- Carfilzomib for injection, 10 mg, 30 mg & 60 mg/vial




SOLID ORALS TABLETS/ CAPSULES

- Sarecycline film coated tablets, 60 mg, 100 mg, and 150 mg
- Saroglitazar Calcium tablets, 2 mg and 4 mg
- Everolimus tablet, 0.25 mg, 0.5 mg, 0.75 mg and 1.0 mg
- Nitisinone tablet, 2 mg, 5 mg and 10 mg

COMPLEX GENERICS (ORAL PEPTIDES)

- Semaglutide Tablets 3 mg, 7 mg, 14 mg
- Linaclotide Hard Gelatin Capsule, 72 mcg, 145 mcg and 290 mcg

COMPLEX NOVEL INJECTABLES

- Triptorelin Acetate microgranules injectable suspension 3.75mg per vial, 11.25 mg per vial; 22.5 mg per vial
 - Leuprolide Acetate for depot suspension (lyophilized microspheres) 3.75 mg, 7.5 mg, 22.5 mg, 30 mg, and 45 mg per vial for injection
 - Octreotide Acetate lyophilized microspheres for injectable suspension, 10 mg, 20 mg or 30 mg per vial strength
- 



Corporate Office: 333-334, Doctor & Doctor, G.I.D.C. Makarpura, Vadodara - 390 010, Gujarat, India.

Email: info@omgene.com | www.omgene.com